June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Author Affiliations & Notes
  • Simone Matsuda
    Cleveland Clinic, Cleveland, OH
  • Tiffany Tam
    Cleveland Clinic, Cleveland, OH
  • Rishi Singh
    Cleveland Clinic, Cleveland, OH
  • Gina Smith
    Cleveland Clinic, Cleveland, OH
  • Justis Ehlers
    Cleveland Clinic, Cleveland, OH
  • Footnotes
    Commercial Relationships Simone Matsuda, None; Tiffany Tam, None; Rishi Singh, Genentech (C), Alcon (C), Bausch and Lomb (R), Zeiss (R), Quark Pharmaceuticals, Inc. (F); Gina Smith, None; Justis Ehlers, Provisional patents filed related to intraoperative OCT technology. No company relationships (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2417. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Simone Matsuda, Tiffany Tam, Rishi Singh, Gina Smith, Justis Ehlers; THE IMPACT OF SYSTEMIC FACTORS ON CLINICAL RESPONSE TO VEGF INHIBITORS FOR DIABETIC MACULAR EDEMA. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2417.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate the effect of glucose regulation, renal function, blood pressure, obesity, and lipid profile on anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME).

Methods: A retrospective consecutive case series for eyes enrolled 125 eyes of 83 patients with DME treated with intravitreal bevacibizumab or ranibizumab. The main outcome measures were the change in best corrected visual acuity (BCVA), the change central subfield macular thickness (CST), the number of intravitreal injections; and their correlation with the serum hemoglobin A1c values (HbA1c), glomerular filtration rate (GFR) estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, fasting serum lipids and other clinical findings.

Results: The study included 125 eyes of 83 patients. Fifty-two (62.6%) females and 72 (86.7%) males with a mean age of 60.4 years were identified. The mean HbA1c was 8.15 (range 6.0-15%) and the mean duration of DM was 11.2 years. The mean initial BCVA was 20/84 and improved to 20/61 at final follow-up (p = 0.02). The mean baseline CSMT was 448 µm and decreased to 366 µm at final follow-up (p < 0.001). The mean number of intravitreal injection was 6.3 and the mean follow-up was 11.9 months. The serum HbA1c values and duration of DM were found to be negatively correlated with the change in CSMT [(-0.33, p < 0.001), (-0.251, p = 0.05), respectively]. Improved glycemic control during the study period (e.g. reduction in HbA1c) was associated with reduced frequency of injections (-0.22; p = 0.05). GFR, blood pressure, and fasting lipid profile did not show significant correlation with change in CST, BCVA or number of intravitreal injections, respectively.

Conclusions: Intravitreal bevacizumab and ranibizumab for DME demonstrated a beneficial functional and structural effect with improved visual acuity and reduced macular edema. Systemic control of diabetes was associated with improved structural response and reduced injection burden. Enhancement of DM control may result in improved response to anti-VEGF therapy. In this study, renal function, blood pressure, and lipid profile did not have a significant impact on response to anti-VEGF therapy.

Keywords: 499 diabetic retinopathy • 748 vascular endothelial growth factor • 505 edema  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.